๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-01-29

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer (NCT04176848)

A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC)

๐Ÿ”ต Active, Not Recruiting Phase2 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Canadian Cancer Trials Group

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.

Who can join: Review the eligibility criteria below.

Location: BCCA - Cancer Centre for the Southern Interior โ€” Kelowna, British Columbia

Age range: 18 Years

๐Ÿงช Interventions in This Study

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (5 Sites)

  • BCCA - Cancer Centre for the Southern Interior โ€” Kelowna, British Columbia
  • Juravinski Cancer Centre at Hamilton Health Sciences โ€” Hamilton, Ontario
  • Kingston Health Sciences Centre โ€” Kingston, Ontario
  • Ottawa Hospital Research Institute โ€” Ottawa, Ontario
  • University Health Network โ€” Toronto, Ontario

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Breast Cancer clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—